The trading price of Regulus Therapeutics Inc (NASDAQ:RGLS) remained unchanged on Monday, May 05, and closing at $7.85.
In examining the 52-week price action we see that the stock hit a 52-week high of $8.20 and a 52-week low of $0.83. Over the past month, the stock has gained 336.11% in value.
Regulus Therapeutics Inc, whose market valuation is $520.01 million at the time of this writing, is expected to release its quarterly earnings report in June. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest RGLS has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned RGLS a recommendation rating is 1. Out of them, 0 rate it a Hold, while 1 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Regulus Therapeutics Inc (RGLS) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that RGLS’s price is currently 133.98% off the SMA20 and 255.67% off the SMA50. The RSI metric on the 14-day chart is currently showing 92.65, and weekly volatility stands at 4.67%. When measured over the past 30 days, the indicator reaches 10.32%. Regulus Therapeutics Inc (NASDAQ:RGLS)’s beta value is currently sitting at 0.39, while the Average True Range indicator is currently displaying 0.50.
To see how Regulus Therapeutics Inc stock has been performing in comparison to its peers in the industry, here are the numbers: RGLS stock’s performance was 0.00% in the latest trading, and 212.75% in the past year.
An evaluation of the daily trading volume of Regulus Therapeutics Inc (NASDAQ:RGLS) indicates that the 3-month average is 1.82 million.
Currently, records show that 65.50 million of the company’s shares remain outstanding. The insiders hold 19.71% of outstanding shares, whereasinstitutions hold 67.85%. However, since the stock’s price has seen 396.84% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
